Table 1.

Patient and Disease Characteristics at the Initiation of Targeted Therapy (N=1158)^a

Variable	Total Cohort (n=1158), %
Median age [range], y	60 [13-89]
Median KPS [range]	80 [30-100]
Men	73.4
>1 Metastatic site	77.4
Brain metastases	8
Prior nephrectomy	80.2
Targeted therapy as first-line therapy	68.6
Type of targeted therapy	68.6
Sunitinib	69.3
Sorafenib	22.7
Bevacizumab	6.6
Temsirolimus	1.2
Axitinib	0.2
MSKCC risk category
Favorable	21.2
Intermediate	56.2
Poor	22.6
Heng criteria risk
Favorable	21.1
Intermediate	50.2
Poor	28.7

KPS indicates Karnofsky performance status; MSKCC, Memorial Sloan-Kettering Cancer Center.

^aThe risk category was unknown in 195 patients (MSKCC) and in 125 patients (Heng criteria; Heng 2009⁸).